TrialSight is a clinical intelligence dashboard purpose-built for pre-commercial biotech companies (10–50 person teams) that need enterprise-grade competitive intelligence without the $200K/year price tag of Citeline, Evaluate, or Informa.
What It Is
An AI-native research platform that aggregates, cross-references, and analyzes data from 10 free public biomedical APIs — delivering KOL mapping, trial outcome forecasting, and competitive landscape monitoring through a single dashboard.
10 Data Sources (All Free Public APIs)
- 1.1. **ClinicalTrials.gov** — Trial registrations, status updates, endpoints, enrollment dataClinicalTrials.gov:
- 2.2. **PubMed / MEDLINE** — Biomedical literature, abstracts, MeSH termsPubMed / MEDLINE:
- 3.3. **OpenAlex** — Citation graphs, author metrics, institutional affiliationsOpenAlex:
- 4.4. **NIH Reporter** — Federal grant awards, funding amounts, PI detailsNIH Reporter:
- 5.5. **FDA OpenFDA** — Drug approvals, adverse events, labeling dataFDA OpenFDA:
- 6.6. **EuropePMC** — European biomedical literature and preprintsEuropePMC:
- 7.7. **UniProt** — Protein/target data for mechanism-of-action mappingUniProt:
- 8.8. **ChEMBL** — Bioactivity data for compound-target relationshipsChEMBL:
- 9.9. **Open Targets** — Disease-target association scoresOpen Targets:
- 10.10. **ICRP** — International cancer research portfolio partnershipsICRP:
No proprietary data purchases. No scraping. Every source is a documented public API.
KOL Intelligence Module
Automatically identifies Key Opinion Leaders for any therapeutic area by cross-referencing:
- >Publication volume and citation impact:
- >Clinical trial involvement:
- >NIH grant funding:
- >Institutional affiliations:
- >Conference activity:
Output: ranked KOL profiles with engagement scores, collaboration maps, and contact pathway suggestions — the kind of analysis that medical affairs teams pay consultants $50K+ to produce manually.
Chorus-Powered Trial Outcome Forecasting
Every monitored trial receives a **TrialSight Score (0–100)** — a calibrated probability estimate of clinical success, generated by Chorus's 17-specialist AI ensemble:
- >Historical phase transition rates for the indication
- >Endpoint design quality and statistical power analysis
- >Competitive trial landscape and differentiation assessment
- >Sponsor track record and financial runway signals
- >KOL involvement correlation with trial success rates
The ensemble approach means no single model's bias dominates — you get a confidence-weighted aggregate with transparent reasoning from each specialist.
Competitive Landscape Monitoring
Real-time alerts when the landscape shifts:
- >New trial registrations in your therapeutic area
- >Competitor trial status changes (enrollment started, results posted, terminated)
- >New publications from competing teams
- >FDA approval decisions on related drugs
- >Grant awards to competing research programs
Alerts are configurable by therapeutic area, mechanism of action, indication, or specific competitor company.
Architecture
Built on four Rising Sun platform components:
- >AAASP:
- >OpenMed:
- >Chorus:
- >ProofStack:
Target Market
Pre-commercial biotech companies (10–50 employees) that are:
- >Post-Series A with active clinical programs
- >Too small for $200K/year enterprise tools (Citeline, Evaluate, Informa)
- >Currently relying on manual PubMed searches and analyst spreadsheets
- >Often found in biotech incubators like PABC (Pennsylvania Biotechnology Center)
Pricing Advantage
Enterprise clinical intelligence tools cost $150K–$250K/year. TrialSight delivers 80% of the insight at 10–20x lower cost by using free public APIs + AI analysis instead of proprietary databases + human analysts.
Tech Stack
Python, FastAPI, PostgreSQL, AAASP (Elixir/OTP), Chorus ensemble API, ProofStack provenance, OpenMed biomedical API layer. Deployed as an AIOS service.